BBS

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Retrieved on: 
Wednesday, September 7, 2022

About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. Rhythm’s precision medicine, setmelanotide, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). The European Commission (EC) has authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. The UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity and is leveraging the Rhythm Engine and the largest known obesity DNA database -- now with approximately 45,000 sequencing samples -- to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. Rhythm’s headquarters is in Boston, MA.

Key Points: 
  • These inducement stock options and inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan").
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to the employees entering into employment with Rhythm pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan was adopted by Rhythms board of directors on February 9, 2022.
  • To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at 833-789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Tuesday, August 2, 2022

-- Entered into non-dilutive revenue interest financing agreement with Healthcare Royalty Partners for up to $100 million, extending cash runway into second half of 2024 --

Key Points: 
  • ET--
    BOSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today reported financial results and provided a business update for the second quarter ended June 30, 2022.
  • R&D Expenses: R&D expenses were$31.5 millionin the second quarter of 2022, as compared to$25.1 millionin the second quarter of 2021.
  • S,G&A Expenses: S,G&A expenses were $22.3 million for the second quarter of 2022, as compared to $15.5 million for the second quarter of 2021.
  • ET today to review its second quarter 2022 financial results and recent business activities.

PreventionGenetics Receives FDA Approval for its Companion Diagnostic Genetic Test as a Class II Medical Device

Retrieved on: 
Thursday, June 30, 2022

MARSHFIELD, Wis., June 30, 2022 /PRNewswire/ -- PreventionGenetics, a subsidiary of Exact Sciences Corp., announced today that it was recently granted marketing authorization for the POMC/PCSK1/LEPR companion diagnostic (CDx) genetic test as a Class II device by the Center for Devices and Radiological Health (CDRH), a division of the Food and Drug Administration (FDA). PreventionGenetics, an accredited germline DNA testing laboratory offering genetic testing to patients and physicians around the world, developed the test in collaboration with Rhythm Pharmaceuticals, Inc.

Key Points: 
  • PreventionGenetics, an accredited germline DNA testing laboratory offering genetic testing to patients and physicians around the world, developed the test in collaboration with Rhythm Pharmaceuticals, Inc.
  • The POMC/PCSK1/LEPR companion diagnostic (CDx) genetic test is for in vitro diagnostic use only and must be ordered by a qualified professional in accordance with clinical laboratory regulations.
  • For more information on PreventionGenetics and the Companion Diagnostic test, visit https://www.preventiongenetics.com/sponsoredTesting/Rhythm/CDX .
  • To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at 833-789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Dah Sing Bank and Friends of the Earth (HK) Jointly Present Property and Construction Industry ESG Forum for SMEs

Retrieved on: 
Monday, June 27, 2022

HONG KONG, June 27, 2022 - (ACN Newswire) - The first industry forum ("the Forum") under the "SME ESG Best Practices Recognition Programme" ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").

Key Points: 
  • HONG KONG, June 27, 2022 - (ACN Newswire) - The first industry forum ("the Forum") under the "SME ESG Best Practices Recognition Programme" ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").
  • ESG implementation may become one of the ways for SMEs to overcome adversity in a down market.
  • Dah Sing Bank, Limited ("Dah Sing Bank") is a wholly-owned subsidiary of Dah Sing Banking Group Limited (HKG:2356) which is listed on the Hong Kong Stock Exchange.
  • In addition to its Hong Kong banking operations, Dah Sing Bank also has wholly-owned subsidiaries including Dah Sing Bank (China) Limited, Banco Comercial de Macau, S.A., and OK Finance Limited.

Black Bourbon Society Partners With Jim Beam® for the 2nd Annual Open Door Tour

Retrieved on: 
Wednesday, June 8, 2022

ATLANTA, June 8, 2022 /PRNewswire/ -- Black Bourbon Society (BBS), is pleased to present the 2nd Annual Open Door Tour, sponsored by Jim Beam® Bourbon. Embodying Jim Beam's inclusive and welcoming nature, the tour will spotlight black-owned bars and restaurants that serve as cultural pillars in their respective communities.

Key Points: 
  • Kicking off on National Bourbon Day, the tour will stop in five US cities this summer featuring panel discussions with local culture makers and cookout-style day parties
    ATLANTA, June 8, 2022 /PRNewswire/ --Black Bourbon Society (BBS), is pleased to present the 2nd Annual Open Door Tour, sponsored by Jim Beam Bourbon.
  • HIGHBALL HOUR - A lively social event highlighting black bartenders and their unique spin on a Jim Beam Highball and cocktails featuring Jim Beam Black.
  • ABOUT JIM BEAM: Jim Beam, the world's best-selling bourbon, has been bringing people together since 1795.
  • Today, the Jim Beam portfolio of products includes Jim Beam Bourbon, Jim Beam Black, Jim Beam Double Oak, Jim Beam Devil's Cut, Jim Beam Rye, Jim Beam Lineage, Jim Beam Old Tub, Jim Beam Vanilla, Jim Beam Honey, Jim Beam Orange, Jim Beam Peach, Jim Beam Apple, Jim Beam Kentucky Fire and Red Stag by Jim Beam among other offerings.

Bangladesh Construction Industry Report 2022: An Expansion of 7.2% Projected for this Year - Forecasts 2023-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 24, 2022

The "Bangladesh Construction Market Size, Trends and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Market Analysis, 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bangladesh Construction Market Size, Trends and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Market Analysis, 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The industry is expected to rebound to growth of 7.2% this year, supported by investments on transport, energy and housing infrastructure projects.
  • he construction industry registered year-on-year (Y-o-Y) growth of 8.3% in FY2020/2021, according to the Bangladesh Bureau of Statistics (BBS).
  • The publisher expects the industry to fare better in 2022, with an expansion of 7.2% projected for the year.

Generational Equity Advises Glacier Glove in its Sale to Elvisridge Capital

Retrieved on: 
Friday, May 6, 2022

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, Glacier Outdoor, LLC (dba Glacier Glove) to Elvisridge Capital, LLC.

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, Glacier Outdoor, LLC (dba Glacier Glove) to Elvisridge Capital, LLC.
  • Located in Reno, Nevada, Glacier Glove (GG), founded in 1982, manufactures and distributes specialty outdoor activity gloves.
  • Glacier Glove will now join Elvisridge Capitals other fishing-related brands, Blackfin Rods and BBS (FINS Fishing), a fishing line manufacturer.
  • Generational Equity , Generational Capital Markets (member FINRA/SIPC), Generational Wealth Advisors , Generational Consulting Group , and DealForce are part of the Generational Group , which is headquartered in Dallas and is one of the leading M&A advisory firms in North America.

Sun Country Airlines Announces Appointment of Patrick O’Keeffe to Board of Directors

Retrieved on: 
Friday, April 29, 2022

“Patrick’s deep experience in airlines both from the technical side as well as the people side -- is valuable perspective as we grow Sun Country’s passenger, cargo and charter service and our people and infrastructure to support that growth,” said Sun Country Airlines CEO Jude Bricker.

Key Points: 
  • MINNEAPOLIS, April 29, 2022 (GLOBE NEWSWIRE) -- Sun Country Airlines ( NASDAQ: SNCY ) has appointed Patrick OKeeffe, former senior human resources officer for American Airlines, to its board of directors effective April 29, 2022.
  • I am pleased to welcome Patrick to our board of directors, said board chair David Siegel.
  • Sun Country will benefit from Patricks long career at American Airlines and his knowledge of talent acquisition, workforce development and information technology.
  • Sun Country Airlines is a new breed of hybrid low-cost air carrier that dynamically deploys shared resources across our synergistic scheduled service, charter and cargo businesses.

Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

Retrieved on: 
Tuesday, April 26, 2022

About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity. Rhythm’s precision medicine, IMCIVREE (setmelanotide), was approved in November 2020 by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing and in July and September 2021, respectively, by the European Commission (EC) and Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. IMCIVREE is the first-ever FDA-approved and EC- and MHRA-authorized therapy for patients with these rare genetic diseases of obesity. The Company submitted a supplemental New Drug Application (sNDA) to the FDA, which was accepted for filing in November 2021 and is currently assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 16, 2022, for the treatment of obesity and control of hunger in adult and pediatric patients six years of age and older with Bardet-Biedl Syndrome (BBS) or Alström syndrome. A Type II variation application to the European Medicines Agency seeking regulatory approval and authorization for setmelanotide to treat obesity and control of hunger in adult and pediatric patients 6 years of age and older with BBS also is under review. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity and is leveraging the Rhythm Engine and the largest known obesity DNA database -- now with approximately 45,000 sequencing samples -- to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. Rhythm’s headquarters is in Boston, MA.

Key Points: 
  • ET on Tuesday, May 3, 2022 to report its first quarter 2022 financial results and provide a corporate update.
  • To access the live conference call, please dial (866) 374-5140 (domestic) or (404) 400-0571 (international) and refer to conference ID 79122322.
  • A webcast of the call will also be available under Events & Presentations in the Investor Relations section of the Rhythm website at ir.rhythmtx.com.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.

Elvisridge Capital Acquires Glacier Outdoor, Inc. dba Glacier Glove

Retrieved on: 
Tuesday, April 26, 2022

Michael Southard, Managing Director of Elvisridge Capital, LLC, is pleased to announce the acquisition of Glacier Outdoor, Inc. (Glacier Glove).

Key Points: 
  • Michael Southard, Managing Director of Elvisridge Capital, LLC, is pleased to announce the acquisition of Glacier Outdoor, Inc. (Glacier Glove).
  • Glacier Glove, based in Reno, Nevada, manufactures gloves and other apparel for the fishing and hunting industries.
  • Glacier will now join Elvisridge Capitals other fishing-related brands, Blackfin Rods and BBS (FINS Fishing), a fishing line manufacturer.
  • Glacier Glove also produces hats, sun hoods, and other sun protection products to help customers extend their outdoor experiences.